Registry of Minimally Invasive Cancer Treatments Using Spectral Angio-CT Guidance

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational registry gathers data from standard-care procedures across multiple European centers in the Netherlands and France. It focuses on image-guided interventional oncology procedures for liver, kidney, lung, and bone cancers, using spectral angio-CT to provide additional imaging information. No experimental treatments are performed; data come from medical records and imaging systems with secure storage. The goal is to understand how the extra spectral data relate to treatment results and how they might enhance future planning, guidance, and evaluation.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years;
* Undergoing a clinically indicated IO procedure with a percutaneous or transarterial approach for solid tumors;
* Use of spectral angio-CT image guidance as part of standard care;
* Written confirmed consent.

Exclusion Criteria:

* Patients who are declared incapacitated;
* Patients suffering from psychic disorders that make a comprehensive judgement impossible.

Where it's running

• Leiden University Medical Center
  Leiden, South Holland, Netherlands Recruiting
• Hospices Civils de Lyon - Hôpital Édouard Herriot
  Lyon, Auvergne-Rhône-Alpes, France Not yet recruiting
• Assistance Publique Hopitaux de Paris - Hôpital Henri Mondor
  Créteil, Île-de-France Region, France Not yet recruiting

Study contacts

• Study coordinator: Emma C.M. Buijsman, MSc
• Email: e.c.m.buijsman@lumc.nl
• Phone: +31 71 526 49 50

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• VMD-102 in liver cancer and other solid tumors

  This study tests VMD-102 to see if it is safe and tolerable and to find the best dose for further study in adults with advanced liver cancer and several other solid tumors.

  Recruiting at 2 sites Phase 1/2 VM Discovery, Inc. · Scottsdale, Arizona and 1 other locations · NCT07636785

• Phase 1 safety and tolerability testing of CTX-10726 in advanced cancers.

  This phase 1 trial will test whether CTX-10726 given by IV every two weeks is safe and tolerable for adults with advanced or metastatic renal cell carcinoma, hepatocellular carcinoma, endometrial, or gastroesophageal cancer who have exhausted standard treatments.

  Recruiting at 8 sites Phase 1 Compass Therapeutics · Phoenix, Arizona and 7 other locations · NCT07419841

• EBNK-001 allogeneic NK cell therapy with low-dose IL-15, with or without pembrolizumab, for advanced solid tumors

  This treatment tests an off-the-shelf NK cell product (EBNK-001) given with low-dose IL-15, either alone or with pembrolizumab, in adults with advanced or metastatic solid tumors who have exhausted standard options.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT07410676

• Sapu003 with or without exemestane for advanced mTOR-sensitive solid tumors

  This phase 1b test will try weekly IV Sapu003, given with exemestane for HR+/HER2- breast cancer or alone for other mTOR-sensitive advanced tumors, to see if it's safe and how your body handles it.

  Recruiting Phase 1 Sapu Nano (Us) LLC · Adelaide · NCT07369505

• Spectral CT during embolization and ablation for liver and kidney tumors

  This pilot tries a new spectral CT technique during image-guided embolization and ablation for adults with liver or kidney tumors to see if it improves image quality and helps guide treatment.

  Recruiting Palo Alto Veterans Institute for Research · Palo Alto, California · NCT07303725

• Boosting lung cancer screening for patients seen in the emergency department

  This project will test whether giving eligible emergency department patients a facilitated referral plus text reminders helps more people get lung cancer screening.

  Recruiting University of Rochester · Rochester, New York · NCT07287085

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.